Table 1.
Demographics and clinical data in patients with persistent PH after left-sided valve replacement (according to the hemodynamic phenotypes) and control individuals.
| Ipc-PH (n = 6) | Cpc-PH (n = 9) | Control (n = 10) | |
|---|---|---|---|
| Baseline clinical data | |||
| Age (years) | 72 ± 3 | 71 ± 5 | 51 ± 4*,† |
| Sex (female/male) | 5/1 | 8/1 | 6/4 |
| Body surface area (m2) | 1.69 ± 0.08 | 1.71 ± 0.05 | 1.8 ± 0.04 |
| WHO FC III–IV (n (%)) | 3 (50) | 7 (78) | 0 (0) |
| MVR (mechanical/biological) | 6/0 | 6/3 | 0 |
| AVR (mechanical/biological) | 2/0 | 3/1 | 0 |
| Atrial fibrillation (n (%)) | 6 (100) | 9 (100) | 0 (0) |
| Medical history (n (%)) | |||
| Hypertension | 2 (33) | 2 (22) | 3 (30) |
| Diabetes | 1 (17) | 2 (22) | 0 (0) |
| Coronary arterial disease | 0 (0) | 0 (0) | 0 (0) |
| Medication (n (%)) | |||
| Oral anticoagulation | 6 (100) | 9 (100) | 0 (0) |
| Loop diuretics | 6 (100) | 9 (100) | 0 (0) |
| ACE inhibitors or ARBs | 5 (83) | 8 (77) | 0 (0) |
| MR antagonists | 2 (33) | 5 (56) | 0 (0) |
Data are presented as mean ± SE unless otherwise specified.
*
P < 0.05 vs. Cpc-PH
†
P < 0.05 vs. Ipc-PH.
AVR/MVR, aortic/mitral valve replacement; ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; Cpc-PH/Ipc-PH, combined pre- and post-capillary/isolated post-capillary pulmonary hypertension; MR, mineralocorticoid receptor; WHO FC, World Health Organization functional class.